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Abstract
Background: Self-reported information is an important tool for collecting clinical information for epidemiologic
studies and in clinical settings where electronic medical records are not employed and shared.
Methods: Using data collected from the Shanghai Breast Cancer Survival Study (SBCSS), a population-based,
prospective cohort study of 5,042 women diagnosed with breast cancer in Shanghai, China, we compared the
concordance of patient questionnaire responses to a survey administered approximately 6 months after cancer
diagnosis with medical chart information obtained from the diagnostic hospitals for several disease and treatment-
related variables.
Results: Of 5,042 SBCSS participants, medical chart information was available for 4,948 women (98.1%).
Concordance between patient self-reported and medical chart information was high for the majority of disease-
related variables, including: diagnosing hospital (agreement: 98.7%, kappa: 0.99), type of surgery conducted (94.0%,
0.53), ER/PR status (94.5%, 0.91), and tumor position (98.2%, 0.97), as well as for important calendar dates, such as
date of diagnosis, surgery, and first chemotherapy treatment. The 10 most commonly used chemotherapeutic
drugs were all reported with agreement rates of at least 82%, with associated kappa values that ranged from 0.41
for calcium folinate to 0.76 for vinorelbine.
Conclusions: Our study found high validity for patient self-reported information for a variety of disease and
treatment-related variables, suggesting the utility of self-reports as an important source of clinical information for
both epidemiological research and patient care.
Background
Epidemiologic studies monitoring clinical information
often rely on data gathered from patient self-reports.
However, not only do self-report instruments such as
interviews or questionnaires depend on adequate patient
comprehension and recall ability, they also are affected
by the wording of questions, the length of recall
required, and the interview setting [1-4]. Measuring the
accuracy of self-reported information is only possible if
the derived data have also been recorded in parallel by a
so-called gold standard such as, arguably, a medical
chart [5]. Studies across several medical specialties have
employed this strategy to validate their respective
patient-reported data [6-10]. However, the vast majority
of such studies analyze medical systems in Western or
otherwise highly developed nations, where electronic
medical records or other methods of optimized informa-
tion sharing are generally available.
Although the investment required to abstract perti-
nent medical record information on a broader scale can
be prohibitive [11], the benefits of validating patient
self-reporting techniques are numerous. Misclassifica-
tions in exposure and outcome assessments could result
in biased risk assessments and a substantial loss of sta-
tistical power in epidemiologic studies. The accuracy of
patient-reported information would also greatly assist in
decisions regarding treatment plans and clinical research
[12,13], particularly in developing countries where medi-
cal record information is often not computerized or
shared among care providers.
T h ep r i m a r yo b j e c t i v eo ft h es t u d yi st op r o v i d ea
comprehensive analysis evaluating the concordance of
self-reported data with medical chart information on
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cohort of 5,042 breast cancer patients living in Shanghai,
China. This study provides information on the utility of
self-reported medical information for use in large-scale
epidemiology studies of cancer outcomes and as a
means of sharing medical information in a developing
nation whose citizens routinely access multiple hospitals
for their care without inter-institution information shar-
ing or a well-established electronic medical records
infrastructure.
Methods
Study population
Study subjects for this analysis are participants of the
Shanghai Breast Cancer Survival Study (SBCSS), a large,
population-based, prospective cohort study of 5,042
women who were diagnosed with breast cancer between
March 2002 and April 2006 and were permanent resi-
dents of Shanghai, China. Details about the SBCSS have
been described previously [14]. In brief, patients were
identified from the population-based Shanghai Cancer
Registry and recruited into the study approximately 6
months after cancer diagnosis. Of the 6,299 identified
cases, 5,042 provided written, informed consent and
participated in the study (participation rate: 80.0%). For
the remaining cases, 757 (12.0%) refused to participate,
258 (4.1%) were absent during study enrollment, 83
(1.3%) could not be contacted, and 159 (2.5%) were
excluded for other miscellaneous reasons such as health
or communication problems.
This study was approved by the institutional review
boards of Vanderbilt University Medical Center and the
Shanghai Municipal Center for Disease Control and
Prevention.
Data collection
Nine trained interviewers, all of them retired medical
professionals, visited study participants’ homes and con-
ducted an in-person interview in which they adminis-
tered the study questionnaire approximately 6 months
after cancer diagnosis. The mean time for each interview
was 67 minutes (standard deviation: 16 minutes). Medi-
cal charts from the time period in which the initial
breast cancer diagnosis occurred were reviewed and per-
tinent information was abstracted using structured ques-
tionnaires. Medical charts were abstracted by 55 tumor
registrars at the hospitals that cared for our study parti-
cipants (over 90% of participants were seen by 31 major
hospitals in Shanghai). Interviewers and tumor registrars
completed separate, rigorous training programs and
were instructed to follow standardized study protocols.
Participants’ medical chart information was not available
to the interviewers who conducted the in-person inter-
views. We also implemented a quality control initiative
in which all information abstracted from the medical
charts was reviewed by the staff of the Shanghai Munici-
pal Center for Disease Control and Prevention, Depart-
ment of Cancer Prevention; errors were identified and
corrected individually by consulting the registrars at the
appropriate hospital.
Information gathered about disease and treatment-
related factors from the questionnaire included: hospital
of diagnosis, occurrence of corrective surgery, dates of
diagnosis and surgery, tumor position, estrogen receptor
(ER) and progesterone receptor (PR) status, surgical pro-
cedures conducted, and chemotherapy or radiotherapy
regimens employed up to approximately 6 months after
cancer diagnosis.
Using a structured questionnaire, tumor registrars col-
lected cancer- and treatment-related information from
each patient’s medical chart from the diagnostic hospi-
tals where patients typically received their initial cancer
treatment. Information gathered included: hospital of
diagnosis, date of breast cancer diagnosis, date of sur-
gery, stage of tumor-node metastasis (TNM) at the time
of primary diagnosis, ER/PR status, types of surgical
procedures (e.g., partial versus radical mastectomy), and
chemotherapy or radiotherapy use. The time period cov-
ered by the medical chart varied from 1 to 3 months.
The reason for this variation was because medical chart
reviews only took place at each patient’s respective diag-
nostic hospital and tumor registrars were instructed
only to collect information related to cancer diagnoses
and the first course of chemotherapeutic regimens. In
Shanghai, it is not uncommon for cancer patients to
receive initial cancer treatment at one hospital and later
switch to other hospitals for further adjuvant treatments.
The decision to limit medical chart abstraction to the
first treatment regimen was partly due to practical
considerations.
Statistical analysis
The focus of our validation study centered on the con-
cordance of patient self-reported data with medical
chart information regarding disease- and treatment-
related variables. Specifically, we analyzed 3 aspects of
the concordance of patient responses with medical chart
data: (1) recall of important diagnostic parameters of
disease, (2) recall of the occurrence and timing of
important disease-related events, and (3) recall of the
use of the 10 most commonly prescribed chemothera-
peutic agents for breast cancer treatment in our cohort.
Tumor position was coded as left breast, right breast, or
both, and most dates were formatted to either the exact
date in Julian code (date coded as the raw number of
days from a predetermined baseline of July 1st 1960 as
day 0) or as a six-digit code (YYYYMM), which was
interpreted manually.
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for normality. The Mann-Whitney rank sum test was
used to compare differences in the median age at diag-
nosis between patients who were included in the study
and those who were excluded. Fisher’se x a c tt e s tw a s
used to compare differences among categorical variables.
Logistic regression analysis was conducted to determine
whether demographic characteristics affected concor-
dance among disease- and treatment-related variables.
The significance levels were set at P < 0.05 for two-
sided analyses. Medical chart information was used as
the gold standard to determine the validity of self-
reported information. Within the current study’sc o n -
text, variables evaluated included: diagnosing hospital,
queries regarding whether an operation was conducted,
the type of operation performed, ER/PR status, and ana-
tomic position of the tumor (left/right/both breasts).
Measures of concordance used were Cohen’s kappa sta-
tistic and percent agreement. Prevalence- and bias-
adjusted kappa was used where the prevalence of a
response was zero (15). The kappa statistic measures the
extent of exact agreement, adjusting for chance agree-
ment with values greater than 0.75 representing excel-
lent concordance; values of 0.40 to 0.75 representing
moderate concordance; and values less than 0.40 repre-
senting poor concordance [15]. All statistical analysis
was performed using STATA SE version 11 (StataCorp.,
College Station, Texas).
Results
Of 5,042 SBCSS participants, medical chart information
was available for 4,948 (98.1%). The age range of our
study participants was 20.5 to 75.0 years at diagnosis
(mean: 53.5 years). Participants with medical chart
information were younger than those without it (median
of 51.1 years vs. median of 54.2 years, P <0 . 0 3 ) ,b u tt h e
two patient groups were otherwise similar regarding
socio-demographic variables such as education level and
per capita income. In addition, they had similar self-
reported treatment-related characteristics (Table 1).
Among our study participants (n = 4,948), 33.95% had
stage I (n = 1,680), 33.25% stage IIa (n = 1,645), 16.92%
stage IIb (n = 837), 9.42% stage III (n = 466), and 0.49%
stage IV (n = 24) breast cancer. Disease stage informa-
tion was missing for 5.98% of study participants (n =
296). All baseline characteristics reported above were
drawn from patients’ medical charts.
The time-gap between the collection of the in-person
interview and the date of diagnosis was a median of 189
days (interquartile range (IQR): 177-202 days), or
approximately 6.5 months. Date of diagnosis was defined
as the day on which a surgically or biopsy-confirmed tis-
sue diagnosis of malignancy was obtained. Conversely,
the time period covered by the information abstracted
from medical charts was a median of 2 months (IQR: 1-
3 months) after cancer diagnosis. Medical chart data
showed that patients generally began chemotherapeutic
regimens at a median of 1 month post-diagnosis (IQR:
1-2 months) and that they typically completed these
regimens within a median of 1 month (IQR: 1-2
months). Patient self-reports represented a median of
127 additional days worth of disease-related information
compared with the medical chart.
Concordance in reporting of diagnostic parameters of
disease
The agreement between both survey instruments on
reporting the correct hospital of diagnosis (98.7%),
Table 1 Baseline Characteristics of Study Participants and Excluded Cases, Shanghai, China, 2002-2006
Characteristic Study cohort (n = 4,948) Excluded cases
a (n = 94) P-value
Median age at diagnosis, (IQR)
b 51.1 (46.4 - 60.5) 55.2 (47.5-66.9) <0.02
Monthly income (yuan) (%)
<500 0.97
500-699 11.1 9.6
700-999 16.5 14.9
1000-1999 29.4 32.0
>2000 31.0 32.0
12.0 11.7
Education level (%) 0.20
<High school 46.4 45.7
High school 37.6 37.2
>High school 16.0 17.1
Received chemotherapy (%) 91.2 89.4 0.47
Received radiotherapy (%) 32.1 33.0 0.83
aExcluded cases represent women enrolled in the Shanghai Breast Cancer Survival Study who had missing patient questionnaire data.
bIQR: Inter-quartile range.
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ER/PR status (94%), tumor position (98%), and type of
surgery (94.0%) was high. Kappa statistics were above
0.9 for all variables except for type of surgery, indicating
excellent concordance. The kappa statistic for type of
surgery was 0.53, indicating moderate concordance
(Table 2).
Concordance in reporting the occurrence of disease-
related events
S i n c et h ep a t i e n ts u r v e yc o v e r e dal o n g e rp e r i o do f
time than the medical chart questionnaire, agreement
and concordance rates for disease- and treatment-
related information were calculated only among
patients who had responses observed in both assess-
ment tools. Patient recall of the occurrence and timing
of important disease-related events was generally in
high agreement with corresponding medical chart data
(Table 3). The concordance in patient reporting of
important dates (to the exact month and year), such as
the date of diagnosis of breast cancer (agreement:
93.5%) or date of surgery (agreement: 86.4%), was high.
In addition, patients were able to accurately recall
whether or not they received chemotherapy or radio-
therapy and also provide accurate time frames for
these courses of treatment, as relevant agreement
values were over 79%. Usage rates for each of these
treatment modalities was consistently higher as
reported by the patient questionnaire relative to the
medical chart, which is likely related to the patient
questionnaire covering a longer period of time.
Further, in most cases, patients were able to report the
dates they received these treatments to within 3 days
of the date recorded by their medical chart. Specifi-
cally, the mean difference in days between the dates of
initiation of radiotherapy and chemotherapy as mea-
sured by both modalities was 2.8 and 1.6, respectively.
These findings suggest that, despite the nearly 4-
month time lag, patients were able to recall therapy
time frames with excellent accuracy.
Accuracy of patient self-report regarding
chemotherapeutic drug usage
Correct reporting of the use of the 10 most common
chemotherapeutic drugs among this cohort of patients
was evaluated and results are presented in Table 4.
Fluorouracil, cyclophosphamide, epirubicin, methotrex-
ate, calcium folinate, pirarubicin, a group of novel drugs,
vinorelbine, docetaxel, and paclitaxel, in that order, were
the 10 most commonly used drugs in our population
according to both surveys (Table 4). Agreement ranged
from 81.7% (epirubicin) to 98.0% (docetaxel) for these
10 agents; the most commonly reported agent, fluroura-
cil, demonstrated high concordance (agreement: 84.9%,
kappa: 0.64). Agreement tended to be higher for less
commonly used drugs compared with more commonly
used drugs, although the kappa statistics varied mod-
estly. The self-reported usage rates for all ten drugs
were consistently higher than rates obtained from medi-
cal charts. Again, this result is likely due to the longer
time period covered by the self-reports.
Finally, we carried out regression analyses to evaluate
whether socio-demographic factors, including age, time
since diagnosis, stage of disease at diagnosis, education
level, or income level, affected the concordance of
patient recall with medical chart information in regards
to both treatment-related and disease-parameter vari-
ables. We found no evidence that the concordance rates
varied by these factors (data not shown).
Discussion
Moderate to excellent concordance between self-
reported and medical chart-based information was
observed for both disease- and treatment-related vari-
ables. Patients accurately reported the dates of their
diagnosis and associated surgical procedures, the loca-
tion of the initial tumor, and ER/PR status. The report-
ing of various treatments, either chemotherapeutic
drugs or otherwise, also demonstrated excellent agree-
ment on most accounts, although the patient question-
naire invariably demonstrated higher usage rates for all
Table 2 Concordance of Patient Responses with Medical Chart Data when Examining Diagnostic Parameters of
Disease, Shanghai, China, 2002-2006
Disease characteristic Number of observations
aAgreement (%) Kappa Sensitivity % (95% CI) Specificity % (95% CI)
Diagnosing hospital 4,943 98.7 0.990 - -
Did you receive an operation? (Yes/No) 4,948 99.4 0.900
b 100.0 (99.9-100.0) 3.2 (0.1-16.7)
Type of surgery conducted 4,917 94.0 0.530 - -
ER/PR
c status 3,637 94.5 0.910 - -
Tumor position 4,948 98.2 0.970 - -
a Percentage of women reporting the exact same response for a given question across both surveys.
b Prevalence- and bias-adjusted Kappa.
c ER: Estrogen receptor; PR: Progesterone receptor
Gupta et al. BMC Medical Research Methodology 2011, 11:72
http://www.biomedcentral.com/1471-2288/11/72
Page 4 of 7forms of therapy, a finding likely attributable to the
longer period of time covered by the patient survey rela-
tive to the medical chart. Levels of concordance did not
vary according to demographic factors.
The high agreement values observed for treatment-
related variables may, in part, be explained by the time-
point at which study participants were interviewed. For
example, breast cancer patients may still be undergoing
adjuvant treatments at 6 months post-diagnosis, which
may have aided in the recall of the treatment variables
measured in our study. Our results are consistent with
prior validation studies conducted among breast cancer
cohorts in Iowa [16] and Quebec [17], particularly in
regards to the high concordance observed with recall of
treatment-related variables and dates of important dis-
ease-related events, such as the date of surgery or the
initiation of chemotherapy. The recall of specific che-
motherapeutic regimens among our Shanghai cohort
was similar to results found in a previous validation
study of 895 breast cancer patients in Melbourne, Aus-
tralia [18], with agreement values ranging from 75% or
greater for the most commonly prescribed regimens
(cyclophosphamide, methotrexate, fluorouracil, doxoru-
bicin, and epirubicin). In all of these studies, the time
between patient interview and diagnosis was at least 1.5
years or greater; thus, the robustness of our self-report
findings at only 6 months post-diagnosis necessitates
future studies to examine significant changes in concor-
dance over time.
The only known prior study that assessed the validity
of self-reports among a disadvantaged or low-income
population similar to our cohort was conducted by Liu
et al. among 726 breast cancer patients aged 18 years or
older living in California, two-thirds of whom had an
average annual income of less than $20,000 [19]. Their
study’s results were remarkably similar to ours in that
>98% of women were able to identify whether they had
undergone surgery for breast cancer, >87% could
Table 3 Concordance in Reporting the Occurrence and Timing of Important Disease-Related Events from Patient
Responses and Medical Chart Data, Shanghai, China, 2002-2006
Name of event
a % reported
in PQ
b
% reported
in MC
c
Number of shared
observations
d
Agreement
(%)
Kappa Sensitivity %
(95% CI)
Specificity %
(95% CI)
Date of diagnosis of breast
cancer
100.0 99.4 4,916 93.5 0.930 - -
Date of surgery 100.0 99.4 4,916 86.4 0.840 - -
Did you receive
chemotherapy? (Yes/No)
100.0 (91.4%
Yes)
100.0 (84.1%
Yes)
4,948 90.1 0.550 98.3 (97.9-98.7) 45.2 (41.7-48.7)
Date started chemotherapy 91.2 83.6 4,068 79.0 0.790 - -
Did you receive radiation
therapy? (Yes/No)
100.0 (32.1%
Yes)
100.0 (4.9%
Yes)
4,948 71.7 0.170 88.9 (84.3-92.6) 70.9 (69.6-72.2)
Date radiation therapy started 32.1 4.93 217 79.3 0.790 - -
a For the purposes of comparison, all dates were either reported or recoded in YYYYMM format in both instruments.
b PQ: Patient questionnaire.
c MC: Medical chart.
d Number of patients across both surveys that had data for a specific question.
Table 4 Concordance of Patient Recall with Medical Chart Data in Reporting Use of the 10 Most Commonly Prescribed
Chemotherapeutic Agents for Breast Cancer Treatment, Shanghai, China, 2002-2006
Chemotherapeutic Agent % that reported use of drug on PQ
a %o fM C
b that reported use of drug Agreement (%) Kappa
Fluorouracil 71.0 68.8 84.9 0.64
Cyclophosphamide 70.1 59.7 82.5 0.62
Epirubicin 52.4 46.0 81.7 0.64
Methotrexate 19.6 16.1 92.1 0.73
Calcium folinate 14.7 14.4 85.4 0.41
Pirarubicin 12.4 8.8 90.8 0.51
Novel drugs
c 9.5 4.7 95.7 0.63
Vinorelbine 8.1 6.9 96.7 0.76
Docetaxel 4.2 2.4 97.8 0.65
Paclitaxel 3.4 2.5 98.0 0.65
a PQ: Patient questionnaire.
b MC: Medical chart.
c Novel drugs include the following list of pharmaceuticals, all of which were approved in China for use in breast cancer patients in 2002, the year both surveys
were conducted: altretamine, oxaliplatin, gemcitabine, trastuzumab, ifosfamide, temozolomide, and Aredia.
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report details of chemotherapeutic regimens, and the
accuracy of recalling dates of diagnoses and surgeries
was within 15 days of the dates documented in the med-
ical records.
Other potential explanations for the high concordance
values observed for most of our diagnosis- and treatment-
related variables include the fact that hospital patients in
Shanghai are given a summary record of information per-
tinent to their hospital visits upon discharge. This infor-
mation includes relevant diagnoses, lab results, treatments
pursued, and the follow-up plan for future care. This
information is succinct, in layman’s terms, and can be
brought by the patient to any hospital establishment that
they visit for their care. However, there is no reliable
metric of how often patients bring this informal hospital
discharge summary to future doctor appointments or
emergency department visits. In addition, given the
emphasis on family and community in Chinese culture,
many patients are accompanied by family members or
close friends to the hospital. This may assist patients with
recall, and in general, having a family member cued into a
patient’s care could certainly help explain our results.
The low concordance values observed for information
related to radiotherapy may best be explained by the dif-
ference in the exposure window covered by each assess-
ment tool and by use of different care providers.
Whereas adjuvant chemotherapy and curative surgery
are common first-line interventions instituted soon after
diagnosis (and hence, likely recorded by the diagnosing
hospital’s medical chart), radiotherapy may only be used
in advanced cases of disease for palliative purposes or in
the event that surgery with chemotherapy did not con-
trol metastatic spread. We see evidence of this in the
differences in numbers between medical chart-abstrac-
tion data and patient self-reports. For example, accord-
ing to medical chart data only 4.93% (n = 244) of
patients received radiotherapy compared with 32.1% (n
= 1,588) according to patient self-reports. Therefore, the
wide gap in rates of report for radiotherapy across both
surveys may be a result of the algorithmic approach to
breast cancer treatment in our cohort: second- and
third-line treatment options that are not employed
immediately after diagnosis were not captured by the
initial medical chart review. A similar problem in rela-
tion to comparing drug usage across surveys conducted
at different points in time has been previously described
in detail [2] and represents a limitation of our study.
Our population-based study design and high response
rate enhance the generalizability of our findings, and
this represents a primary strength of our study. The
structured questionnaires that were used in the survey
and medical chart review helped to reduce misclassifica-
tions and errors during data abstraction. Given that
multiple diagnostic hospitals were involved in the study,
in addition to the lack of standardization in the record-
ing of medical chart information for research purposes,
misclassifications when analyzing the medical chart data
are likely. Therefore, the agreement rates that we
observed in our study are likely to be underestimated.
Conclusion
In summary, our study showed excellent concordance in
the reporting of essential disease- and treatment-related
information between the medical chart and patient self-
report among breast cancer patients 6 months after
diagnosis. Among our most important findings was
breast cancer patients’ ability to recall the use of specific
chemotherapeutic drugs, in addition to various diagnos-
tic characteristics of their disease. Taken together, our
results have significant implications for conducting
population-based studies among breast cancer patients,
as the collection of medical information via hospital
records can be both cost-prohibitive and logistically
complicated, because of concerns regarding patient con-
fidentiality. While our results are not necessarily applic-
able to populations globally, in settings where patients
seek medical care at multiple hospitals for practical or
financial considerations, as is often the case in China,
our findings reinforce the utility of patient self-report as
an accurate means of obtaining medical data to guide
data collection and clinical decision-making.
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